Carriers of the reduced-function CYP2C19 allele receiving dual antiplatelet therapy (DAPT) with aspirin and clopidogrel exhibit diminished platelet inhibition and an increased risk of events. The purpose of this study was to investigate the effects of CYP2C19 gene variants on platelet function tests and coagulation and inflammatory biomarkers in patients undergoing elective percutaneous coronary intervention (PCI). Methods: This prospective, observational, multicenter study enrolled 104 consecutive Japanese patients undergoing elective PCI. We examined the CYP2C19 genotype, platelet function tests, the levels of coagulation and inflammatory biomarkers and the serum levels of high-sensitivity troponin T (hsTnT) before, immediately after and one, two and 28 days after PCI. Results: A total of 68 (65%) of the 104 enrolled patients were carriers of the CYP2C19 reducedfunction allele. On-clopidogrel platelet aggregation (PA), measured using light transmittance aggregometry and the VerifyNow ® P2Y12 system, and the platelet reactivity index (PRI) were significantly higher at all time points in the carriers than in the noncarriers (p＜0.05), whereas there were no differences in the levels of the coagulation and inflammatory biomarkers or serum hs-TnT. Simple and multiple logistic regression analyses identified on-clopidogrel PA and PRI as being significant predictors of carriers of the CYP2C19 reduced-function allele. Conclusions: The present study suggests that platelet function tests, but not coagulation, inflammatory or cardiac biomarkers, are useful for identifying carriers of CYP2C19 reduced-function gene variants and monitoring the efficacy of DAPT in patients undergoing elective PCI. J Atheroscler Thromb, 2014; 21:64-76.
Introduction
Platelet activation plays an important role in the onset of acute coronary syndrome (ACS) 1) . Disrup-tion of coronary atherosclerotic plaque exposes the thrombogenic material in the lipid-rich core of the plaque to the blood, causing platelet adhesion and activation as well as thrombin generation. The activated platelets undergo morphological changes and release vasoactive and procoagulant substances, followed by conformational changes in the membrane glycoprotein Ⅱb/Ⅲa receptor that allow for fibrinogen cross-linking and platelet aggregation. Dual antiplatelet therapy (DAPT) consisting of aspirin and clopidogrel is currently used to regulate activated platelets in
Platelet Function Tests
Platelet function tests and assays for blood biomarkers of coagulation activation and inflammation were performed before, immediately after and one, disrupted coronary plaques in ACS patients and to reduce atherothrombotic complications in ACS patients undergoing percutaneous coronary intervention (PCI) [2] [3] [4] [5] [6] [7] [8] [9] . Observational studies have demonstrated that a high level of on-clopidogrel platelet aggregation (PA) can result in adverse cardiovascular events after PCI, including stent thrombosis [10] [11] [12] [13] . In this regard, carriers of at least one reduced-function cytochrome P450 2C19 (CYP2C19) allele treated with DAPT have been reported to have low levels of the active metabolites of clopidogrel, diminished platelet inhibition and a high rate of major adverse cardiovascular events among ACS patients undergoing PCI 14) . Based on the clinical outcomes of patients with ACS undergoing PCI, recent studies have advocated the use of careful monitoring of the on-clopidogrel PA level using various platelet function assays 15, 16) . In a previous study, we also demonstrated the efficacy of on-clopidogrel PA monitoring by showing the cutoff level of on-clopidogrel PA that can be used to discriminate carriers of the functional CYP2C19 reducedfunction allele among patients with stable coronary artery disease (CAD) treated with clopidogrel 17) . However, it is not clear whether CYP2C19 gene variants influence serial changes in platelet function tests and blood coagulation and inflammatory biomarkers in stable CAD patients undergoing elective PCI. We therefore conducted a CALDERA-PCI (CYP2C19 gene ALteration and thienopyriDinE ResistAnce in PCI; NCT00876512) study, a prospective, observational, multicenter study that enrolled 104 consecutive Japanese patients with stable CAD scheduled to undergo elective PCI.
Aim
The present study was designed to further examine the effects of CYP2C19 gene variants on platelet function tests in stable CAD patients undergoing elective PCI. The tests included measurements of the level of on-clopidogrel PA [measured using light transmittance aggregometry (LTA) and the VerifyNow ® P2Y12 system], the platelet reactivity index (PRI) that is the difference in vasodilator-stimulated phosphoprotein (VASP) fluorescence intensity between resting and activated platelets, and platelet adhesiveness. We also measured blood coagulation and inflammatory biomarkers [von-Willebrand factor (VWF), VWF-cleaving protease (ADAMTS13), soluble P-selectin (sPselectin), soluble CD40 ligand (sCD40L), interleukin-6 (IL-6), soluble intercellular adhesion molecule-1 (sICAM-1) and high-sensitivity C-reactive protein (hs-CRP)] and a cardiac biomarker [serum high-sensi-
Measurement of Blood Coagulation and Inflammatory Biomarkers
Venous blood samples were obtained before, immediately after and one, two and 28 days after elective PCI. At the time of sampling, the first 3 mL of blood was obtained for biochemical assessment, and the subsequent 4.5 mL of venous blood was collected in a sequential manner into an evacuated tube containing 0.5 mL of sodium citrate solution (0.13 mol/L, pH 7.5). All blood samples were immediately centrifuged at 1,700 g for 10 minutes at 4 ℃, and aliquots of the samples were stored at −80 ℃ until the analysis.
The plasma VWF antigen levels were measured using a sandwich enzyme-linked immunosorbent assay (ELISA) kit (Asserachrom VWF; Roche, Tokyo) according to the instructions supplied by the manufacturer. The plasma ADAMTS13 antigen levels were measured using sandwich ELISA with a polyclonal antibody against ADAMTS13, as previously reported 22) . The plasma levels of other biomarkers for coagulation activation, such as sP-selectin and sCD40L, and markers of inflammation, such as IL-6 and sICAM-1, were measured using ELISA kits (sP-selectin: Takara Shuzo Co, Tokyo, sCD40L: R&D Systems, Oxford, UK, IL-6: R&D Systems and sICAM-1: eBioscience; Vienna, Austria) according to the instructions provided by the supplier. The serum hs-TnT levels were also measured (Elecsys 2010 analyzer, Roche Diagnostics, Mannheim, Germany) as previously described 23) .
Determination of the CYP2C19 Genotype and Phenotype
Genomic DNA was extracted from whole blood using the DNA Extractor WB kit (Wako Pure Chemical Industries, Osaka, Japan) and the modified protocol of Richards et al. 24) . PCR restriction fragment length polymorphisms (RFLPs) for CYP2C19 ＊ 2 (681G＞A) and CYP2C19 ＊ 3 (636G＞A) were obtained as previously described 25) . The CYP2C19 genotype was classified into three phenotypes: an extensive metabolizer (EM) carrying normal function alleles (CYP2C19 
Assessment of Clinical Outcomes
After undergoing laboratory sampling and elective PCI, all patients received standard medical therapy and were followed for a maximum of six months or with visits until the occurrence of the clinical end point. The clinical end point was a major cardiac or cerebrovascular event, such as cardiac death, nonfatal two and 28 days after elective PCI. Blood sampling before PCI was performed at least one week after aspirin treatment and at least 24 hours after clopidogrel loading just before elective PCI. The blood samples were collected using the double-syringe technique, in which the first 2 to 4 mL of blood was discarded to prevent spontaneous platelet activation.
The on-clopidogrel PA levels were measured using LTA (MCM HEMA TRACER 313M, MC Medical, Inc., Tokyo, Japan) and the VerifyNow ® P2Y12 system (Ultegra rapid platelet function assay; Accumetrics Inc., San Diego, CA). The Vacutainer was inverted three to five times for gentle mixing and sent immediately to the laboratory. For LTA, the blood samples were drawn into Vacutainer tubes containing 0.5 mL of 3.2% sodium citrate (Becton-Dickinson, San Jose, CA) and processed within 60 minutes. LTA was performed at all time points using 20 μmol/L of adenosine diphosphate (ADP) as an agonist. The relative maximum LTA response (maximum response to 20 μmol/L ADP) and area under the curve (platelet aggregation area to 20 μmol/L ADP) during a period of 10 minutes were recorded. For the VerifyNow ® assay, the blood samples for each time point for the P2Y12 cartridge were drawn into two 1.8-mL blood collection tubes containing 3.2% sodium citrate and analyzed independently. Fibrinogen-coated microparticles are used in the P2Y12 cartridge to bind to available platelet receptors 18) . The results are reported in P2Y12 reaction units (PRU), which represent the amount of ADP-mediated aggregation specific to the platelet P2Y12 receptor. The PRU values were determined based on the rate and extent of platelet reactivity (by way of aggregation) in the ADP channel. Another separate channel contained fibrinogen-coated polystyrene beads and iso-thrombin receptor activating peptide (iso-TRAP) as an agonist, and the baseline value (BASE) was obtained. The %inhibition was calculated as: [(BASE-PRU)/BASE] X 100, which represents the difference between the pre-and posttreatment values.
The VASP phosphorylation state of whole blood was measured using a standardized flow cytometric assay, which is an adaptation of the method of Schwarz et al. 19) . The PRI (expressed as a percentage), which reflects the difference in VASP fluorescence intensity between resting (＋PGE1) and activated (＋ADP) platelets, was calculated from the median fluorescence intensity (MFI) of samples incubated with prostaglandin E1 (PGE1) or PGE1 and ADP according to the formula: PRI = [(MFI(PGE1)−MFI(PGE1＋ADP)) / MFI(PGE1)]× 100 20) . Platelet adhesiveness was measured as previously described 21) .
of 0.05, a sample of 100 patients was required. The data are expressed as the mean±standard deviation. Categorical data are presented as frequencies and percentages. Differences between carriers and noncarriers were tested using the chi-square test (and Fisher's exact test) for categorical variables. Differences in continuous variables were analyzed using the unpaired t -test and Mann-Whitney U test. The statistical significance of changes in the time course of the platelet function tests and biomarkers between carriers and noncarriers was evaluated using a one-way analysis of variance for repeated measures. Associations between the presence of carriers of at least one myocardial infarction, unstable angina pectoris or ischemic stroke.
Statistical Analysis
Based on the data described previously regarding the on-clopidogrel PA levels in the carriers and noncarriers of the CYP2C19 reduced-function allele 26) , we hypothesized that the mean difference in the rate of inhibition of platelet aggregation between carriers and noncarriers of the CYP2C19 reduced-function allele would be 14% with a standard deviation of 20%. Therefore, in order to detect a statistically significant difference with a power of 90% and a two-sided α-level 10 (15) 19 (29) 56 (82) 44 (65) 36 (53) 35 (51) 22 (32) 40 (59) 38 (56) 30 (44) 48 (71) 20 (42) 20 (29) 4 (20) 12 (33) 11 (31) 31 (86) 25 (69) 24 (67) 19 (53) 9 (25) 18 (50) 26 (72) 20 (56) 32 (89) 13 (41) 15 (42) 2 (13) The data are presented as the mean±SD or n (%). CYP = cytochrome P450; ISDN = isosorbide dinitrate, CCB = calcium-channel blocker; ACE-I = angiotensin-converting enzyme antagonist; ARB = angiotensin Ⅱ receptor antagonist; PPI = proton pump inhibitor; eGFR = estimated glomerular filtration rate and 36 (35%) patients were noncarriers (EM). The clinical characteristics of the carriers and noncarriers are listed in Tables 1 and 2 . There were no significant differences between the carriers and noncarriers in baseline characteristics known to be associated with platelet aggregation. Table 1 also lists the medication history in each group at the time of the baseline blood sampling. The proportions of patients receiving isosorbide dinitrate, calcium channel blockers, angiotensin-converting enzyme inhibitors, angiotensin Ⅱ receptor blockers, β-blockers and proton pump inhibitors were identical in the two groups, while the use of statins was more frequent in the noncarriers than in the carriers.
Clinical Outcomes and Serial Changes in the Platelet Function Tests and Blood Levels of Coagulation and Inflammatory Biomarkers in the Carriers and Noncarriers
As shown in Fig. 1 , platelet inhibition measured using LTA (20 μmol/L ADP-maximal platelet reactivity (PRmax) and 20 μmol/L ADP-PR area), the VerifyNow ® P2Y12 system (PRU and %inhibition) and the PRI (VASP phosphorylation index), but not platelet adhesiveness, was diminished in the carriers comreduced-function CYP2C19 allele and other significant parameters that have been shown to influence the platelet function in recent studies [27] [28] [29] [30] [31] were analyzed using a multiple logistic regression analysis with the forced entry method. The Hosmer-Lemeshow statistic was applied to assess model calibration. A p value of ＜0.05 denoted statistical significance. The statistical analyses were performed using the Statistical Package for Social Sciences version 18 software program (SPSS Inc., Tokyo, Japan).
Results

Patient Characteristics and the Frequency of the CYP2C19 Genotypes and Phenotypes
Of the 104 patients [80 men and 24 women, 68.7±9.5 years of age (mean±SD, range, 42-89)] who underwent PCI and were treated with aspirin and clopidogrel, the distribution of the CYP2C19 genotype was 36 (35%) patients, 41 (39%) patients, 14 (13%) patients, eight (8%) patients, three (3%) patients and two (2%) patients for The data are presented as the mean±SD. ADP-PRmax = ADP-induced platelet reactivity maximum aggregation; ADP-PR area = ADP-induced platelet reactivity area; PRU = P2Y12 reaction unit; PRI = platelet reactivity index [the index of vasodilator-stimulated phosphoprotein (VASP) phosphorylation], VWF = von-Willebrand factor; ADAMTS13 = the 13th member of the ADAMTS (a disintegrin-like domain and metalloprotease with thrombospondin type 1 motif ) family; sCD40L = soluble CD40 ligand; sPselectin = soluble P-selectin; IL-6 = intrerleukin-6; sICAM-1 = soluble Intercellular adhesion molecule-1; hs-CRP = highsensitivity C-reactive protein; hs-TnT = high-sensitivity troponin T ious blood biomarkers for coagulation activation and inflammation at all time points. The plasma levels of VWF, ADAMTS13, sP-selectin, sCD40 ligand, IL-6, sICAM-1 and hs-CRP were identical between the carpared to that observed in the noncarriers at all time points. The levels of on-clopidogrel PA were significantly increased immediately after compared with before PCI. Fig. 2 and 3 demonstrate the levels of var- PRU, %inhibition and PRI before PCI were correlated with the presence of carriers of the CYP2C19 reduced-function allele among the examined patients (Table 3) . However, the other platelet function parameter (platelet adhesion), the coagulation and inflammatory biomarkers (VWF, ADAMTS13, sP-selectin, sCD40L, IL-6, sICAM-1 and hs-CRP) and the serum hs-TnT levels were not correlated with a carriers status. A multiple logistic regression analysis identified the four on-clopidogrel PA parameters (20 μmol/L of ADP-PRmax, 20 μmol/L of ADP-PR area, PRU and %inhibition) and the PRI as being significant predictors of carriers of the CYP2C19 reduced-function allele among the stable CAD patients [odds ratio (OR) 13 Table 4 ). These models were reliable when each parameter of the plateriers and noncarriers at all time points. The serum cardiac hs-TnT levels were increased significantly at one and two days after compared with before PCI in both groups, while the levels were identical between the two groups at all time points.
During the follow-up period, only one carrier patient developed ischemic stroke, while no major cardiac or cerebrovascular events were observed in the noncarriers.
Simple and Multiple Logistic Regression Analyses to Predict the Occurrence of Carriers of the CYP2C19 Reduced-Function Allele
We examined whether the above parameters measured before PCI could be used to predict carriers of the CYP2C19 reduced-function allele among stable CAD patients undergoing PCI on DAPT. function tests and blood biomarkers of coagulation activation and inflammation in stable CAD patients undergoing elective PCI. To the best of our knowledge, this is the first report to show a relationship between CYP2C19 reduced-function gene variants, platelet function tests and blood biomarkers for coagulation activation and inflammation in stable CAD patients undergoing elective PCI. Recent studies 14, 32) have shown that, among the functional genetic variants of CYP genes, carriers of at least one CYP2C19 reduced-function allele have significantly lower levels of the active metabolites of clopidogrel, reduced platelet inhibition and a higher rate of major adverse cardiovascular events (MACE), including stent thrombosis, than noncarriers among ACS patients treated with clopidogrel for PCI. However, few patients develop MACE after PCI among 
Discussion
The present study demonstrated that the onclopidogrel PA level and PRI, but not blood coagulation or inflammatory biomarkers, are predictors of CYP2C19 reduced-function gene variants in stable CAD patients undergoing elective PCI on DAPT. Although carriers of the reduced-function CYP2C19 allele on DAPT exhibit diminished platelet inhibition and are at higher risk after ACS, it was not clear whether CYP2C19 gene variants influence platelet tion activation and markers of inflammation are thought to play important roles in the pathogenesis of atherothrombotic complications, such as acute or subacute stent thrombosis, in patients undergoing PCI. In regard to this point, it has been demonstrated that, in patients undergoing PCI, a high clopidogrel maintenance dose is associated with stronger platelet inhibition, an improvement of the endothelial function and a reduction of inflammation compared with the currently recommended 75-mg/day regimen 34) and that the 75-mg/day clopidogrel regimen differentially affects platelet aggregation and platelet-induced patients with stable CAD. In this regard, subclinical intrastent thrombosis has been reported to be more common in CYP2C19 ＊ 2 carriers than in noncarriers on follow-up OCT after DES implantation among stable CAD patients 33) , although the same study reported a lower frequency of MACE in both the carriers and noncarriers 33) . Based on these observations, the development of medical treatments that can be used to discriminate the risk of reduced-function CYP2C19 gene variants is needed, even for patients with stable CAD treated with DAPT.
Several blood biomarkers of platelet and coagula- , Left ventricular ejection fraction ＞60%, PRU ＞230, % Inhibition ＜24%, PRI ＞50%, hs-TnT ＞40 ng/mL.
b Data for these parameters were divided into two groups based on the median value. The abbreviations are as in Tables 1 and 2. lor, at baseline, discharge and four weeks. The CURE study also reported similar findings: that clopidogrel did not suppress biomarkers of coagulation activation in aspirin-treated patients with non-ST elevation ACS 37) , although the authors did not discuss the relationship between CYP2C19 reduced-function gene variants and biomarkers of platelets and coagulation activation. A potential explanation for the present finding is patient selection; the enrolled patients were low-risk stable CAD patients with less marked platelet and coagulation activation and a lower inflammatory status, thereby limiting the statistical power of this study to detect differences in these markers between the carriers and noncarriers. However, the baseline characteristics and rates of clinical events were similar, while the on-clopidogrel PA levels measured using LTA, PRU and %inhibition were significantly different between the two groups, and the study population size was determined using a power analysis. Therefore, the lack of statistical power is unlikely to account for inflammation in ACS patients within the first month of treatment 35) . Because the frequency of CYP2C19 reduced-function gene variants is higher in Japanese individuals (65% of the total population) than in Westerners (approximately 30% of the total population), it is possible that these biomarkers are affected by CYP2C19 reduced-function alleles in the Japanese population. Based on these observations, we hypothesize that CYP2C19 reduced-function gene variants alter the levels of blood biomarkers of coagulation activation and inflammation in CAD patients undergoing PCI treated with DAPT. However, our results showed that there were no significant differences in the levels of such biomarkers or the serum hs-TnT levels at any time point between the carriers and noncarriers. In this regard, Husted et al. 36) reported that, in their study, inflammatory biomarkers, such as CRP, IL-6, myeloperoxidase and sCD40L, were not significantly different between treatment groups of clopidogrel and the potent P2Y12 receptor inhibitor, ticagre- 0.914 a Data for these parameters were divided into two groups based on the same criteria as in Table 3 . The abbreviations are as in Tables 1, 2 and 3 .
Conclusion
In summary, the present study demonstrated that carriers of the CYP2C19 reduced-function allele treated with DAPT have abnormal on-clopidogrel PA levels and PRI values, but not cardiac hs-TnT levels or biomarkers of coagulation activation or inflammation. These tests are potentially valuable for identifying such carriers and monitoring the efficacy of DAPT in Japanese patients undergoing elective PCI.
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In the present study, the on-clopidogrel PA level and PRI were found to be factors associated with the presence of the CYP2C19 reduced-function allele in patients with stable CAD undergoing elective PCI. LTA is considered to be a standard test that includes measurements of the on-clopidogrel PA levels in CAD patients receiving dual antiplatelet therapy 11, 15, 38) . However, LTA has certain drawbacks in measuring platelet aggregation, such as the long sample processing time and need for expert personnel. The PRI (the VASP phosphorylation state of whole blood), which is measured using a standardized flow cytometric assay, is also useful for assessing on-clopidogrel platelet reactivity, although it is not a rapid assay system. On the other hand, the VerifyNow ® P2Y12 system is an easyto-use point-of-care system designed to measure platelet reactivity to various antiplatelet agents 18) , allowing for real-time monitoring of the PA levels in CAD patients treated with clopidogrel. In our previous study, we demonstrated that the on-clopidogrel PA level determined by the PRU and %inhibition was significantly correlated with that measured using LTA, confirming the reliability of the VerifyNow ® P2Y12 system for measuring the on-clopidogrel PA levels in CAD patients undergoing elective PCI. Therefore, the present results demonstrate the usefulness of the onclopidogrel PA level measured according to the PRU and %inhibition for predicting the presence of the CYP2C19 reduced-function allele in stable CAD patients undergoing elective PCI.
The present study found that carriers of the CYP2C19 reduced-function allele constituted 65% of the patients, compared with a noncarrier rate of 35%. In a recent study of healthy Westerners, the prevalence of carriers of the CYP2C19 reduced-function allele was 30% in the total study population 14) . However, adverse cardiovascular events, including stent thrombosis after primary or elective PCI, are lower in Japanese individuals than in Westerners [39] [40] [41] , although the frequency of carriers of at least one CYP2C19 reduced-function allele is higher in Japanese patients than Western patients. The reason for the low risk of adverse cardiovascular events, including stent thrombosis, in Japan remains unknown; however, it is possible that other factors, such as the PCI procedure, the characteristics of the culprit coronary plaques or coronary risk factors, in addition to platelet aggregation, may influence the clinical outcomes of CAD patients treated with clopidogrel.
